BioSphere Medical, Inc. (NASDAQ: BSMD), the medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, announced today that it plans to issue financial results for the first quarter on April 26, 2007 before the market opens. Management will conduct a conference call that morning at 11:00 a.m. Eastern Time to discuss these results. The number to dial into the teleconference is 1-888-603-7990 or 1-706-679-7298 for international callers. The conference ID is 5833529. Please call in approximately ten minutes before the call is scheduled to begin. The call is also being webcast by Thomson Financial and can be accessed at BioSphere Medical's web site: www.biospheremed.com.

A replay of the teleconference will be available from 2:00 p.m. Eastern Time on April 26, 2007 through 2:00 p.m. Eastern Time on May 10, 2007. The replay dial-in number is 1-800-642-1687 or 1-706-645-9291 for international callers. The code for the replay is 5833529. A replay of the webcast will be available at the investor section of BioSphere Medical's website at www.biospheremed.com.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Risk Factors" in BioSphere's Annual Report on Form 10-k for the year ended December 31, 2006, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise.